Analysis found 25% tariff on pharmaceutical imports would hike U.S. drug costs by nearly $51 billion annually, boosting ...

Novavax shows financial improvement but faces vaccine challenges. Read why I rated NVAX stock as 'Hold' and what risks and ...

The FDA, which was supposed to decide by April 1 whether it would approve Novavax's application for a full license, is seeking more clinical studies of the vaccine. Now, because other drugmakers ...

Confusion over the FDA delay in granting full approval to Novavax’s Covid-19 vaccine deepened over the weekend, with possible ...

Under emergency use, vaccines can be removed even after a health emergency is considered to be over. Full approval from the FDA means a product can stay on the market even after a health emergency ...

After a 20% cut to the FDA’s workforce, biotechs and pharmas are bracing for delays. But the impacts won’t be consistent.

Takeda, a Japanese pharmaceutical company, plans to launch its dengue vaccine, Qdenga, in India next year in collaboration with Biological E. Clinical trials are underway, and the company aims to ...

A study published last week suggests that, if vaccine uptake continues to decline, measles will soon be endemic again in the ...

Novavax, Inc. (NVAX) shares jumped nearly 12.6% over the past week, leading to a surge in retail investor chatter following ...

A summary of current health news, including the disbanding of a U.S. Justice Department unit focusing on food and drug safety ...

The FDA has discussed with vaccine-maker Novavax the need for an additional trial of its COVID-19 vaccine as a post-approval ...